膀胱内注射肉毒素治疗膀胱过度活动症的研究进展

doi:10.6040/j.issn.1671-7554.0.2017.1207

摘要/Abstract

摘要： 对于M受体阻滞剂治疗无效或不耐受的难治性膀胱过度活动症(OAB)患者,膀胱内注射肉毒素(BTX)是一项安全、有效的治疗手段。BTX膀胱内注射后,通过与神经肌接头处的突触前膜结合,进而阻止前膜释放乙酰胆碱,引起特定肌肉可恢复性的迟缓性麻痹而起到治疗作用。BTX治疗难治性OAB的临床效果已得到广泛验证,且适用于儿童、糖尿病及老年OAB患者。通过分析文献,对注射BTX的适应证及禁忌证,BTX产品种类及用量、注射方法、疗效与影响因素、不良反应及其干预措施等方面进行总结与探讨,以期为BTX注射这一疗法的临床应用提供更详实的参考与指导。

关键词: 肉毒素, 膀胱过度活动症, 抗毒蕈碱药

Abstract: Intravesical botulinumtoxin(BTX)injection has been proved to be a safe and effective treatment for intrac-table overactive bladder syndrome(OAB)that is refractory to antimuscarinics. This review is going to highlight the major progresses of this technique to provide a detailed picture for its clinical applications. The biological properties of BTX and its working mechanisms will be introduced first, and then, the properties of BTX products from different companies, indications and contraindications of this technique, the right injected dosage and appropriate sites of injection, effects and adverse effects will be stated and discussed. Meanwhile, the effects of BTX injection in specific groups of patients like children, diabetes mellitus(DM)patients and elderly people will be explored.

Key words: Botulinumtoxin, Overactive bladder, Antimuscarinics

中图分类号:

R694

张秀琳. 膀胱内注射肉毒素治疗膀胱过度活动症的研究进展[J]. 山东大学学报 (医学版), 2018, 56(3): 12-18.

ZHANG Xiulin. Advances in the treatment of overactive bladder by intravesical botulinumtoxin injection[J]. Journal of Shandong University (Health Sciences), 2018, 56(3): 12-18.

参考文献

[1] 那彦群, 孙光, 叶章群, 等. 2014版中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2013: 628.
[2] Groen J, Pannek J, Castro Diaz D, et al. Summary of European Association of Urology(EAU)Guidelines on Neuro-Urology[J]. Eur Urol, 2016, 69(2): 324-333.
[3] Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder(non-neurogenic)in adults: AUA/SUFU guideline amendment[J]. J Urol, 2015, 193(5): 1572-1580.
[4] Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review[J]. Int Urogynecol J, 2017, 28(6): 805-816.
[5] Osman NI, Chapple CR. Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches[J]. Arab J Urol, 2013, 11(4): 313-318.
[6] Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics[J]. J Urol, 2006, 176(1): 177-185.
[7] Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome[J]. Indian J Urol, 2013, 29(1): 2-11.
[8] Knippschild S, Frohme C, Olbert P, et al. Value of nerve growth factor levels in overactive bladder syndrome: alterations after botulinum toxin therapy[J]. Urologe A, 2012, 51(3): 379-383.
[9] 付伟金, 莫曾南. A型肉毒杆菌毒素治疗膀胱过度活动症研究进展[J]. 临床泌尿外科杂志, 2006(3): 234-237.
[10] Ravindra P, Jackson BL, Parkinson RJ. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA(Botox((R)))or abobotulinumtoxinA(Dysport((R)))make a difference?[J]. BJU Int, 2013, 112(1): 94-99.
[11] Seth J, Khan MS, Dasgupta P, et al. Botulinum toxin-what urologic uses does the data support?[J]. Curr Urol Rep, 2013, 14(3): 227-234.
[12] Chapple C, Sievert KD, Macdiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial[J]. Eur Urol, 2013, 64(2): 249-256.
[13] Denys P, le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study[J]. Eur Urol, 2012, 61(3): 520-529.
[14] Jabs C, Carleton E. Efficacy of botulinum toxin a intradetrusor injections for non-neurogenic urinary urge incontinence: a randomized double-blind controlled trial[J]. J Obstet Gynaecol Can, 2013, 35(1): 53-60.
[15] Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women(the RELAX study)[J]. Eur Urol, 2012, 62(3): 507-514.
[16] Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder[J]. Urol Ann, 2011, 3(2): 66-70.
[17] Chapple CR. Finding the correct starting dose for onabotulinumtoxinA[J]. Eur Urol, 2012, 61(3): 530-532.
[18] Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial[J]. J Urol, 2010, 184(6): 2416-2422.
[19] Cohen BL, Barboglio P, Rodriguez D, et al. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units[J]. Neurourol Urodyn, 2009, 28(3): 205-208.
[20] Sahai A, Kalsi V, Khan MS, et al. Techniques for the intradetrusor administration of botulinum toxin[J]. BJU Int, 2006, 97(4): 675-678.
[21] Manecksha RP, Cullen IM, Ahmad S, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity[J]. Eur Urol, 2012, 61(5): 928-935.
[22] Lucioni A, Rapp DE, Gong EM, et al. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection[J]. Can J Urol, 2006, 13(5): 3291-3295.
[23] Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics[J]. Neurourol Urodyn, 2011, 30(7): 1242-1248.
[24] Alloussi SH, Lang C, Eichel R, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction(NBD)and idiopathic detrusor overactivity(IDO)refractory to drug treatment[J]. World J Urol, 2012, 30(3): 367-373.
[25] Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction[J]. Eur Urol, 2005, 48(6): 984-990.
[26] Krhut J, Samal V, Nemec D, et al. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study[J]. Spinal Cord, 2012, 50(12): 904-907.
[27] Okamura K, Nojiri Y, Ameda K, et al. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes[J]. Int J Urol, 2011, 18(6): 483-487.
[28] Dowson C, Watkins J, Khan MS, et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates[J]. Eur Urol, 2012, 61(4): 834-839.
[29] Game X, Khan S, Panicker JN, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity[J]. BJU Int, 2011, 107(11): 1786-1792.
[30] Granese R, Adile G, Gugliotta G, et al. Botox((R))for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection[J]. Arch Gynecol Obstet, 2012, 286(4): 923-929.
[31] Mohee A, Khan A, Harris N, et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder(OAB)[J]. BJU Int, 2013, 111(1): 106-113.
[32] Veeratterapillay R, Harding C, Teo L, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity[J]. Int J Urol, 2014, 21(2): 175-178.
[33] Abeywickrama L, Arunkalaivanan A, Quinlan M. Repeated botulinum toxin type A(Dysport)injections for women with intractable detrusor overactivity: a prospective outcome study[J]. Int Urogynecol J, 2014, 25(5): 601-605.
[34] Sahai A, Khan MS, le Gall N, et al. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder[J]. Urology, 2008, 71(3): 455-459.
[35] Makovey I, Davis T, Guralnick ML, et al. Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability[J]. Neurourol Urodyn, 2011, 30(8): 1538-1540.
[36] Lie KY, Wong MY, Ng LG. Botulinum toxin a for idiopathic detrusor overactivity[J]. Ann Acad Med Singapore, 2010, 39(9): 714-715.
[37] Schulte-Baukloh H, Bigalke H, Heine G, et al. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection[J]. Urology, 2007, 69(3): 513-575.
[38] Hegele A, Frohme C, Varga Z, et al. Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance[J]. Urol Int, 2011, 87(4): 439-444.
[39] Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection[J]. J Urol, 2008, 180(1): 217-222.
[40] Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics[J]. Urology, 2005, 66(1): 94-98.
[41] King AB, Rapp DE. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity[J]. Can J Urol, 2011, 18(2): 5657-5659.
[42] Bauer RM, Gratzke C, Roosen A, et al. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome[J]. Urol Int, 2011, 86(1): 68-72.
[43] Marte A, Borrelli M, Sabatino MD, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children[J]. Eur J Pediatr Surg, 2010, 20(3): 153-157.
[44] Lawrence JM, Lukacz ES, Liu IL, et al. Pelvic floor disorders, diabetes, and obesity in women: findings from the Kaiser Permanente Continence Associated Risk Epidemiology Study[J]. Diabetes Care, 2007, 30(10): 2536-2541.
[45] Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity[J]. Neurourol Urodyn, 2014, 33(8): 1235-1239.
[46] Liao CH, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity[J]. J Urol, 2013, 189(5): 1804-1810.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed